Cargando…

Anti-Tumor Effect of Apatinib and Relevant Mechanisms in Liposarcoma

BACKGROUND: Primary retroperitoneal liposarcomas (RLPSs) are rare heterogeneous tumors for which there are few effective therapies. Certain anti-angiogenic tyrosine kinase inhibitors have demonstrated efficacy against various solid tumors. The aims of this study were to investigate the effect of Apa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cui, Lixuan, Yan, Liang, Guan, Xiaoya, Dong, Bin, Zhao, Min, Lv, Ang, Liu, Daoning, Wang, Zhen, Liu, Faqiang, Wu, Jianhui, Tian, Xiuyun, Hao, Chunyi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8637299/ https://www.ncbi.nlm.nih.gov/pubmed/34868934 http://dx.doi.org/10.3389/fonc.2021.739139

Ejemplares similares

Tsp2 Facilitates Tumor-associated Fibroblasts Formation and Promotes Tumor Progression in Retroperitoneal Liposarcoma
por: Xu, Chang, et al.
Publicado: (2022)

Establishment and evaluation of retroperitoneal liposarcoma patient-derived xenograft models: an ideal model for preclinical study
por: Xu, Chang, et al.
Publicado: (2022)

Expression and function of Siglec-15 in RLPS and its correlation with PD-L1: Bioinformatics Analysis and Clinicopathological Evidence
por: Cui, Lixuan, et al.
Publicado: (2022)

Identification of the γ-glutamyl cycle as a novel therapeutic target and 5-oxoproline as a new biomarker for diagnosing pancreatic cancer
por: Wang, Weijia, et al.
Publicado: (2023)

Comprehensive immune characterization and T‐cell receptor repertoire heterogeneity of retroperitoneal liposarcoma
por: Yan, Liang, et al.
Publicado: (2019)

Downregulation of RRM2 Attenuates Retroperitoneal Liposarcoma Progression via the Akt/mTOR/4EBP1 Pathway: Clinical, Biological, and Therapeutic Significance
por: Zhang, Sha, et al.
Publicado: (2020)

Identification of TYMS as a promoting factor of retroperitoneal liposarcoma progression: Bioinformatics analysis and biological evidence
por: Zhang, Sha, et al.
Publicado: (2020)

Identification of an Immune-Related Signature for Predicting Prognosis in Patients With Pancreatic Ductal Adenocarcinoma
por: Wang, Weijia, et al.
Publicado: (2021)

PTK7 overexpression in colorectal tumors: Clinicopathological correlation and prognosis relevance
por: Tian, Xiuyun, et al.
Publicado: (2016)

SKP2 High Expression, KIT Exon 11 Deletions, and Gastrointestinal Bleeding as Predictors of Poor Prognosis in Primary Gastrointestinal Stromal Tumors
por: Lv, Ang, et al.
Publicado: (2013)

Efficacy and safety of anlotinib plus camrelizumab in treating retroperitoneal soft tissue sarcomas: a single-center retrospective cohort study
por: Wu, Jianhui, et al.
Publicado: (2023)

Effective apatinib treatment of pleomorphic liposarcoma: A case report
por: Yan, Peng, et al.
Publicado: (2017)

CD26 as a Promising Biomarker for Predicting Prognosis in Patients with Pancreatic Tumors
por: Yan, Liang, et al.
Publicado: (2020)

T cell receptor β‐chain repertoire analysis of tumor‐infiltrating lymphocytes in pancreatic cancer
por: Cui, Can, et al.
Publicado: (2018)

Treatment Response, Survival Benefit and Safety Profile of PD-1 Inhibitor Plus Apatinib Versus Apatinib Monotherapy in Advanced Colorectal Cancer Patients
por: Pan, Dengdeng, et al.
Publicado: (2022)

Apatinib plus chemotherapy for non-metastatic osteosarcoma: a retrospective cohort study
por: Wang, Jiaqiang, et al.
Publicado: (2023)

Efficacy and Response Biomarkers of Apatinib in the Treatment of Malignancies in China: A Review
por: Tian, Zhichao, et al.
Publicado: (2021)

Expression of CD147 and matrix metalloproteinase-11 in colorectal cancer and their relationship to clinicopathological features
por: Tian, Xiuyun, et al.
Publicado: (2015)

Case Report: Gastrointestinal PEComa With TFE3 Rearrangement Treated With Anti-VEGFR TKI Apatinib
por: Xu, Jiaming, et al.
Publicado: (2020)

Case report: Two cases of primary paratesticular liposarcoma
por: Li, Jiaxing, et al.
Publicado: (2022)

Apatinib Treatment in Metastatic Gastrointestinal Stromal Tumor
por: Cai, Zhaolun, et al.
Publicado: (2019)

Apatinib combined with PD-1 antibody for third-line or later treatment of advanced gastric cancer
por: Cui, Qingli, et al.
Publicado: (2022)

Transarterial chemoembolization plus apatinib with or without camrelizumab for unresected hepatocellular carcinoma: A two-center propensity score matching study
por: Zhu, Di, et al.
Publicado: (2022)

A case report of perineal liposarcoma
por: Sakly, Aymen, et al.
Publicado: (2019)

Fatty tumors of the retroperitoneum: Lipoma or well-differentiated liposarcoma. About a case of a giant retroperitoneal liposarcoma
por: bibi, Mokhtar, et al.
Publicado: (2018)

Downregulation of TfR1 promotes progression of colorectal cancer via the JAK/STAT pathway
por: Cui, Can, et al.
Publicado: (2019)

Anti-PD-1 Immunotherapy and Bee Venom for Relapsed and Refractory Liposarcoma: A Case Report
por: Yang, Wei, et al.
Publicado: (2021)

Activity and safety of apatinib monotherapy or apatinib combined with chemotherapy for patients with metastatic or unresectable osteosarcoma over the age of 40 years: A retrospective analysis
por: Gong, Taojun, et al.
Publicado: (2022)

Assessment of Efficiency and Safety of Apatinib in Advanced Bone and Soft Tissue Sarcomas: A Systematic Review and Meta-Analysis
por: Long, Zuoyao, et al.
Publicado: (2021)

Features and Treatment of Peritoneal Metastases from Solid Pseudopapillary Neoplasms of the Pancreas
por: Wu, Jianhui, et al.
Publicado: (2018)

About a case of paratesticular myxoid liposarcoma
por: Ayari, Yassine, et al.
Publicado: (2018)

A rare case of liposarcoma of the spermatic cord
por: Dunev, V.R., et al.
Publicado: (2020)

Primary myxoid liposarcoma of the pelvis: An unusual location
por: Rico Gala, Susana, et al.
Publicado: (2020)

Transarterial Chemoembolization Combined With Apatinib for Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis
por: Kan, Xuefeng, et al.
Publicado: (2020)

Expression of p53 as a biomarker in determining response to apatinib for advanced gastric cancer
por: Qiu, Zhiyuan, et al.
Publicado: (2023)

Apatinib Plus Temozolomide: An Effective Salvage Treatment for Recurrent Glioblastoma
por: Ge, Jingjing, et al.
Publicado: (2021)

Dedifferentiated liposarcoma of the left kidney: A rare case report
por: Li, Chiao-Ching, et al.
Publicado: (2018)

Apatinib Plus Camrelizumab With/Without Chemoembolization for Hepatocellular Carcinoma: A Real-World Experience of a Single Center
por: Ju, Shuguang, et al.
Publicado: (2022)

The anti-tumor efficiency of low-dose apatinib-based chemotherapy in pretreated HER2-negative breast cancer with brain metastases
por: Chen, Xuelian, et al.
Publicado: (2023)

Case Report: Low-Dose Apatinib in the Treatment of Intrahepatic Biliary Cystadenoma With Recurrence and Malignant Transformation
por: Yang, Yongguang, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_2luj57qkeps1m3fthqg8amep3u